Nicole Doria-Rose | |
---|---|
Born | 1970 (age 53–54) |
Alma mater | Cornell University (BA, PhD) |
Scientific career | |
Fields | Humoral immunity |
Institutions | Vaccine Research Center |
Thesis | In vivo selection of Rous sarcoma virus mutants with randomized sequences in the packaging signal (1998) |
Doctoral advisor | Volker Vogt |
Nicole Amy Doria-Rose (born 1970) [1] is an American biologist. She is chief of the humoral immunology core at the Vaccine Research Center. She develops and applies assays to evaluate HIV-1 specific antibody responses during natural infection and after immunization.
Doria-Rose graduated from Hunter College High School in New York City in 1987. She obtained her Bachelor of Arts in biology in 1991 and a Ph.D. in 1998 from Cornell University. During her doctoral studies, she trained under advisor Volker Vogt in the department of biochemistry, molecular and cell biology. [2] Her dissertation was titled In vivo selection of Rous sarcoma virus mutants with randomized sequences in the packaging signal. [1]
From 1998 to 2003, Doria-Rose worked as a postdoctoral scientist in the laboratory of Nancy Haigwood at the Seattle Biomedical Research Institute (SBRI) and the department of pathobiology at University of Washington. Doria-Rose was promoted to the position of associate scientist at SBRI in 2003. While working as a post-doctoral fellow, Doria-Rose was also appointed as associate faculty in the science department at Shoreline Community College in 2000. [2]
Doria-Rose joined the National Institute of Allergy and Infectious Diseases in 2006 as a senior research fellow in the laboratory of immunoregulation. In 2011, she became a staff scientist at the Vaccine Research Center, where she has worked on isolating new, potent anti-HIV monoclonal antibodies and studying their development over time. In 2012, she was promoted to the position of Chief of the humoral immunology core. [2]
Doria-Rose develops and applies assays to evaluate HIV-1 specific antibody responses during natural infection and after immunization. [2]
A DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence into the cells of an organism as a mechanism to induce an immune response.
An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals. It is thought that an HIV vaccine could either induce an immune response against HIV or consist of preformed antibodies against HIV.
Howard Martin Temin was an American geneticist and virologist. He discovered reverse transcriptase in the 1970s at the University of Wisconsin–Madison, for which he shared the 1975 Nobel Prize in Physiology or Medicine with Renato Dulbecco and David Baltimore.
The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
This is a list of AIDS-related topics, many of which were originally taken from the public domain U.S. Department of Health Glossary of HIV/AIDS-Related Terms, 4th Edition.
The Wistar Institute is an independent, nonprofit research institution in biomedical science with special focuses in oncology, immunology, infectious disease, and vaccine research. Located on Spruce Street in the University City section of Philadelphia, Wistar was founded in 1892 as a nonprofit institution to focus on biomedical research and training.
In immunology, passive immunity is the transfer of active humoral immunity of ready-made antibodies. Passive immunity can occur naturally, when maternal antibodies are transferred to the fetus through the placenta, and it can also be induced artificially, when high levels of antibodies specific to a pathogen or toxin are transferred to non-immune persons through blood products that contain antibodies, such as in immunoglobulin therapy or antiserum therapy. Passive immunization is used when there is a high risk of infection and insufficient time for the body to develop its own immune response, or to reduce the symptoms of ongoing or immunosuppressive diseases. Passive immunization can be provided when people cannot synthesize antibodies, and when they have been exposed to a disease that they do not have immunity against.
La Jolla Institute for Immunology (LJI) is a non-profit research organization in La Jolla, a community of San Diego, California. The institute was founded in 1988. It is located in UC San Diego’s Research Park. The institute researches immunology and immune system diseases. The institute employs 220 M.D.s and Ph.D.s, including 23 faculty members and more than 450 employees. Dr. Erica Ollmann Saphire has served as its president and CEO since 2021.
The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.
Barton Ford Haynes is an American physician and immunologist internationally recognized for work in T-cell immunology, retrovirology, and HIV vaccine development. Haynes is a Frederic M. Hanes Professor of Medicine and Immunology at Duke University Medical Center. He is the director of the Duke Human Vaccine Institute and the Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), which was funded by the National Institute of Allergy and Infectious Diseases (NIAID) in 2012. In addition, Haynes directs the B-cell Lineage Envelope Design Study, the Centralized Envelope Phase I Study, and the Role of IgA in HIV-1 Protection Study as part of the Collaboration for AIDS Vaccine Discovery (CAVD), which was funded by the Bill and Melinda Gates Foundation in 2006.
Deborah Persaud is a Guyanese-born American virologist who primarily works on HIV/AIDS at Johns Hopkins Children's Center.
Julie E. Ledgerwood is an American allergist and immunologist, who is the chief medical officer and chief of the Clinical Trials Program at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in Bethesda, Maryland. She is a Doctor of Osteopathic Medicine.
Robert Harry Purcell is an American virologist and former co-chief of the Laboratory of Infectious Diseases at the U.S. National Institute of Allergy and Infectious Disease. He is known for his work on hepatitis viruses, and was involved in identifying hepatitis A virus, hepatitis D virus, and hepatitis E virus, developing an animal model for hepatitis B, and developing the hepatitis A vaccine.
Gary J. Nabel is an American virologist and immunologist. He is the President and chief executive officer of ModeX Therapeutics in Natick, Massachusetts. He was the founding director of Vaccine Research Center at the National Institute of Allergy and Infectious Diseases.
A Zika virus vaccine is designed to prevent the symptoms and complications of Zika virus infection in humans. As Zika virus infection of pregnant women may result in congenital defects in the newborn, the vaccine will attempt to protect against congenital Zika syndrome during the current or any future outbreak. As of April 2019, no vaccines have been approved for clinical use, however a number of vaccines are currently in clinical trials. The goal of a Zika virus vaccine is to produce specific antibodies against the Zika virus to prevent infection and severe disease. The challenges in developing a safe and effective vaccine include limiting side effects such as Guillain-Barré syndrome, a potential consequence of Zika virus infection. Additionally, as dengue virus is closely related to Zika virus, the vaccine needs to minimize the possibility of antibody-dependent enhancement of dengue virus infection.
Kizzmekia "Kizzy" Shanta Corbett is an American viral immunologist. She is an Assistant Professor of Immunology and Infectious Diseases at Harvard T.H. Chan School of Public Health and the Shutzer Assistant Professor at the Harvard Radcliffe Institute since June 2021.
Nancy Jean Sullivan is an American cell biologist researching filovirus immunology and vaccine development. She is a senior investigator and chief of the biodefense research section at the Vaccine Research Center. Her team discovered the monoclonal antibody, mAb114.
Vanessa M. Hirsch is a Canadian-American veterinary pathologist and scientist. She is a senior investigator and chief of the nonhuman primate virology section at the National Institute of Allergy and Infectious Diseases. Hirsch researches AIDS pathogenesis, the evolution and origins of primate lentiviruses, and HIV vaccine development.
John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.
Harriet Latham Robinson is an American vaccine researcher who is founder and Chief Scientific Officer Emeritus at GeoVax. She is the former Chief of Microbiology and Immunology at the Yerkes National Primate Research Center and Asa Griggs Candler Professor of Microbiology at Emory University. Her research considered HIV vaccine development. She is a Fellow of the American Association for the Advancement of Science.
{{cite book}}
: |journal=
ignored (help)